Chemours Q3 net loss $27M on $56M impairment; adjusted EPS $0.40; TSS Opteon sales up 21%

Chemours Co

2024-Q3 EPS reported $0.63 revenue$4,388,000,000

Net loss of $27M ($0.18/diluted share) due to $56M non-cash impairment of APM goodwill.
Net sales $1.5B (+1% YoY); TSS record sales with Opteon refrigerants up 21% YoY.
Adjusted EBITDA $208M vs $211M; TT segment Adjusted EBITDA up 23% YoY.
Cash returned $38M in dividends; refreshed corporate strategy designed for sustainable growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.